Eli Lilly Archives

Latest Posts

News and Trends 13 Oct 2022

Merck contributing to Jacobio Pharma colorectal cancer clinical trial

Jacobio announced it has entered into a clinical trial collaboration agreement with Merck on a clinical study of combination therapy between Jacobio's KRAS G12C inhibitor JAB-21822 and Merck's epidermal growth…

October 13, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 1 Sep 2022

Study of injection to treat schizophrenia to begin after $3M payment received

A phase 3 clinical trial for an injection to treat patients with schizophrenia has been initiated after a $3 million payment was received by MedinCell. Teva Pharmaceuticals made the decision…

September 1, 2022 - 2 minutesmins - By Liza Laws

News and Trends 3 Apr 2020

Lilly Partners UK Immunometabolism Biotech in Deal Worth €811M

Eli Lilly will partner Oxford-based Sitryx to develop up to four drug candidates to treat autoimmune disease in a deal worth €811M if development milestones are met. The UK biotech…

April 3, 2020 - 2 minutesmins - By Helen Albert

More News! 23 Sep 2019

AC Immune Gets €28M from Eli Lilly as Alzheimer’s Drug Hits Phase I

AC Immune will receive €27.6M (CHF 30M) from big pharma Eli Lilly as it begins a phase I trial of its first-in-class Alzheimer’s disease drug. This is the first milestone…

September 23, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 6 Sep 2018

Insulin Combo Reduces After-Meal Sugar Spikes in Type 1 Diabetics

In the midst of a legal litigation with Eli Lilly, Adocia has released Phase 1 data showing its insulin combo can outperform Lilly’s fast-acting insulin in keeping sugar levels low…

September 6, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Feb 2018

Novo Nordisk Gets Close to Launching the First Oral GLP-1 Drug for Diabetes

Novo Nordisk has positive Phase III trial results for its oral version of semaglutide, a GLP-1 based treatment for type II diabetes. This could be the first oral GLP-1 treatment…

February 23, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 30 Sep 2019

Update: Mixed Results for Adocia as Legal Fight with Eli Lilly Comes to a Close

Update (30/09/2019): A long legal battle between Adocia and Eli Lilly over a fast-acting insulin treatment development deal has finished with mixed results for Adocia. Eli Lilly has now paid…

September 30, 2019 - 4 minutesmins - By Editorial Team

News and Trends 13 Feb 2018

Watch Out Eli Lilly: Novo’s Diabetes Drug Ozempic Gets European Approval

Update (13/02/2018): The European Commission has given Novo Nordisk a market authorization for Ozempic (semaglutide), bringing the competition for Eli Lilly's Trulicity over to Europe. Eli Lilly executives have said that…

February 13, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

alzheimers disease phase iii UK 1 e1557338331863

News and Trends 24 Mar 2020

Eli Lilly Sweetens AC Immune Alzheimer’s Treatment Deal by €38M

A deal between Swiss biotech AC Immune and Eli Lilly to develop an oral Alzheimer’s disease drug has increased in worth by €38M with a new milestone payment. AC Immune…

March 24, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 18 Oct 2017

Eli Lilly Offers German Biotech up to €1.5Bn to Develop mRNA Cancer Vaccines

CureVac will be working with pharma giant Eli Lilly in the development of up to five cancer vaccines based on mRNA technology. Eli Lilly will pay CureVac $50M (€43M) upfront and…

October 18, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Eli Lilly Topas Therapeutics Autoimmune Disease

News and Trends 22 Aug 2017

Eli Lilly Partners with German Biotech Against Autoimmune Disease

Topas Therapeutics has signed a multi-year agreement with Eli Lilly to develop drug candidates for antigen-specific immunotherapy. The young Topas Therapeutics, a spin off from Evotec launched just last year, has managed to…

August 22, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Novo Nordisk Semaglutide GLP 1 receptor agonist type 2 diabetes Eli Lilly Trulicity dulaglutide

More News! 18 Aug 2017

Novo Nordisk’s New Type 2 Diabetes Drug Outperforms Eli Lilly’s

Novo Nordisk has reported Phase III data that reveal its candidate semaglutide improved glucose control and weight loss in type 2 diabetes when compared with Eli Lilly's dulaglutide. The results…

August 18, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

Download Inpart’s latest report

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering